Medizinische Hochschule Hannover, Klinik für Kardiologie und Angiologie, Rebirth-Cluster of Excellence, Carl-Neuberg Str.1, 30625, Hannover, Germany.
J Cachexia Sarcopenia Muscle. 2012 Sep;3(3):145-8. doi: 10.1007/s13539-012-0081-7. Epub 2012 Aug 2.
The term sarcopenia describes the age-related loss of skeletal muscle mass and function. While this process, in principal, occurs in every adult person and already starts around the age of 40, it is associated with disability, morbidity, and increased mortality in some individuals. In the absence of clear clinical manifestation, we today lack the ability to differentiate between physiological and pathological sarcopenia. In this regard, we need good biomarkers that can be quantified in a reliable, cost-effective manner and that guide diagnosis and therapy of pathological sarcopenia in routine clinical practice and clinical trials. We suggest that a combination of serum markers, diagnostic imaging, and functional tests of muscle function would constitute an ideal biomarker panel. Importantly, sarcopenia biomarkers will have to be tested and validated in clinical trials.
术语“肌肉减少症”描述了与年龄相关的骨骼肌量和功能的丧失。虽然这个过程在理论上发生在每个成年人身上，并且已经在 40 岁左右开始，但它与某些人的残疾、发病和死亡率增加有关。在没有明确的临床症状的情况下，我们目前缺乏区分生理性和病理性肌肉减少症的能力。在这方面，我们需要良好的生物标志物，这些标志物可以以可靠且具有成本效益的方式进行定量，并指导病理性肌肉减少症的常规临床实践和临床试验中的诊断和治疗。我们建议将血清标志物、诊断成像和肌肉功能的功能测试相结合，构成一个理想的生物标志物组合。重要的是，肌肉减少症生物标志物将需要在临床试验中进行测试和验证。
